Literature DB >> 31996563

A Cross-sectional Study of Group B Streptococcus-Associated Sepsis, Coinfections, and Antibiotic Susceptibility Profile in Neonates in Pakistan.

Samra Asghar1, Junaid Ali Khan, Muhammad Shahid Mahmood, Muhammad Imran Arshad.   

Abstract

BACKGROUND: Neonatal sepsis is a leading cause of morbidity and early-life mortality worldwide, and previous data have reported the highest neonatal mortality rate in Pakistan.
PURPOSE: The present study aimed to decipher the prevalence of group B Streptococcus (GBS)-associated sepsis, coinfections, and antibiotic susceptibility of isolated microbes in neonates.
METHODS: Blood samples of 100 cases of neonatal sepsis were subcultured on blood agar, GBS agar, and MacConkey agar for isolation of GBS and suspected microbes.
RESULTS: Of 100 neonatal blood samples, 85 blood samples were culture-positive, including mixed culture growth (n = 18), 25 samples as early-onset neonatal sepsis (EONS) and 60 as late-onset neonatal sepsis (LONS). Staphylococcus aureus showed high percent positivity (31.4%), followed by Candida sp (16.5%), GBS (14.1%), Klebsiella (14.1%), Staphylococcus epidermidis (11.8%), Pseudomonas (9.4%), Acinetobacter (9.4%), Esherichia coli (8.2%), and Enterococcus (5.9%). GBS was isolated more frequently from EONS than from LONS with 50% coinfections. Mode of delivery, gender, and respiratory distress in neonates were significantly associated with culture-positive sepsis. GBS isolates were highly (91.7%) susceptible to vancomycin, cefotaxime, and chloramphenicol, followed by penicillin (83.3%), ampicillin, and tetracycline (75%). GBS isolates were resistant to erythromycin, clindamycin, ciprofloxacin, and linezolid. IMPLICATIONS FOR PRACTICE: Our findings evidenced GBS-associated risk factors and antibiotic susceptibility pattern of neonatal sepsis, which will help clinicians in management, control, and treatment of neonatal sepsis. IMPLICATIONS FOR RESEARCH: The epidemiological evidence of GBS-associated neonatal sepsis, demographic characteristics, risk factor data analysis, and drug resistance pattern has disease prevention implications in neonates in low-income countries including Pakistan.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31996563     DOI: 10.1097/ANC.0000000000000701

Source DB:  PubMed          Journal:  Adv Neonatal Care        ISSN: 1536-0903            Impact factor:   1.968


  5 in total

1.  Effect of intrapartum antibiotic prophylaxis of group B streptococcus infection on the incidence and bacteriological profile of early-onset neonatal sepsis.

Authors:  Zhou-Jie Peng; Lei Bao
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2022-01-15

2.  Accurate 16S Absolute Quantification Sequencing Revealed Vaginal Microecological Composition and Dynamics During Mixed Vaginitis Treatment With Fufang FuRong Effervescent Suppository.

Authors:  Meng Li; Zhen Zeng; Huijun Feng; Yang Cao; Qiongqiong Zhang; Tao Lv; Xingsheng Yang; Dianrong Song; Ping Li; Lina Hu; Shangrong Fan; Ruifang An; Bei Zhang; Lei Zhang; Qinping Liao
Journal:  Front Cell Infect Microbiol       Date:  2022-05-13       Impact factor: 6.073

3.  Antimicrobial resistance in colonizing group B Streptococcus among pregnant women from a hospital in Vietnam.

Authors:  Vu Van Du; Pham Thai Dung; Nguyen Linh Toan; Can Van Mao; Nguyen Thanh Bac; Hoang Van Tong; Ho Anh Son; Nghiem Duc Thuan; Nguyen Thanh Viet
Journal:  Sci Rep       Date:  2021-10-21       Impact factor: 4.379

Review 4.  Early-Onset Neonatal Sepsis in Low- and Middle-Income Countries: Current Challenges and Future Opportunities.

Authors:  Kirsty Sands; Owen B Spiller; Kathryn Thomson; Edward A R Portal; Kenneth C Iregbu; Timothy R Walsh
Journal:  Infect Drug Resist       Date:  2022-03-09       Impact factor: 4.003

5.  Risk Factors and Clinical Characteristics of Neonatal Acute Respiratory Distress Syndrome Caused by Early Onset Sepsis.

Authors:  Ting You; Yan-Rong Zhou; Xiao-Chen Liu; Lu-Quan Li
Journal:  Front Pediatr       Date:  2022-03-28       Impact factor: 3.418

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.